This company has been marked as potentially delisted and may not be actively trading. Rapt Therapeutics (RAPT) FDA Approvals Add Compare Share Share FDA Events Stock AnalysisAnalyst ForecastsEarningsFDA EventsInsider TradesNews and TrendsOwnership Rapt Therapeutics' Drug in the FDA Approval ProcessThis section highlights FDA-related milestones and regulatory updates for drugs developed by Rapt Therapeutics (RAPT). Over the past two years, Rapt Therapeutics has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as RPT904. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. RPT904 FDA Regulatory Timeline and Events RPT904 is a drug developed by Rapt Therapeutics for the following indication: Food Allergy. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy. Trial Initiation - October 27,2025Trial Initiation Phase 2bDrug: RPT904Announced Date: October 27, 2025Indication: Food AllergyAnnouncement RAPT Therapeutics, Inc announced that it has initiated the randomized, double-blind, placebo-controlled prestIgE Phase 2b clinical trial of ozureprubart (formerly RPT904) in IgE-mediated food allergy.AI SummaryRAPT Therapeutics, Inc. has launched the prestIgE Phase 2b trial of ozureprubart (formerly RPT904), a half-life extended anti-IgE antibody, in patients with IgE-mediated food allergies. This randomized, double-blind, placebo-controlled study will enroll about 100 participants across 30 sites in the U.S., Canada and Australia. Participants with peanut, milk, egg, walnut or cashew allergies will receive ozureprubart subcutaneously every eight or 12 weeks (with a second loading dose) or placebo, in a 2:2:1 ratio. The primary endpoint is the percentage of subjects who reach a prespecified tolerance threshold during a double-blind, placebo-controlled oral food challenge at Week 24. Brian Wong, M.D., Ph.D., RAPT’s CEO, said the trial builds on strong early data and aims to offer patients a more durable, less frequent dosing option. Hugh Sampson, M.D., highlighted ozureprubart’s potential as a transformative bio-better to omalizumab.Read AnnouncementTop-line results - October 20,2025Top-Line Results Phase 2Drug: RPT904Announced Date: October 20, 2025Indication: Food AllergyAnnouncementRAPT Therapeutics, Inc. announced positive topline data from Jeyou's Phase 2 trial of RPT904 (JYB1904) as monotherapy in chronic spontaneous urticaria (CSU).AI SummaryRAPT Therapeutics announced positive topline data from Shanghai Jeyou’s Phase 2 trial of RPT904 (JYB1904) in adults with chronic spontaneous urticaria (CSU). In this randomized, double-blind study, 137 patients received 300 mg of RPT904 either every eight weeks (Q8W) or as a single dose every twelve weeks (Q12W), while a comparator arm received 300 mg of omalizumab every four weeks (Q4W). Both RPT904 schedules produced numerically greater reductions in the seven-day UAS7 symptom score at Weeks 8, 12 and 16, and higher rates of complete symptom relief (UAS7 = 0), compared to omalizumab Q4W. Efficacy was sustained through Week 16 after one RPT904 dose. RPT904 was well tolerated, with no serious adverse events related to the study drug. Based on these results, Jeyou plans to advance RPT904 into Phase 3 development in China, and RAPT will discuss its global Phase 3 path with the FDA. RAPT will host a conference call at 8:30 am ET today to review these data.Read AnnouncementTop-line data - October 19,2025Top-Line Data Phase 2Drug: RPT904Announced Date: October 19, 2025Indication: Food AllergyAnnouncementRAPT Therapeutics, Inc. announced that the Company plans to report topline data from the Phase 2 clinical trial of RPT904 (JYB1904) in patients with Chronic Spontaneous Urticaria (CSU) conducted by its partner, Shanghai Jeyou Pharmaceutical Co., Ltd.AI SummaryRAPT Therapeutics, Inc. plans to share topline results from its partner Shanghai Jeyou Pharmaceutical’s Phase 2 clinical trial of RPT904 (JYB1904) in patients with Chronic Spontaneous Urticaria (CSU). The company will release data in a premarket press release and webcast on Monday, October 20, 2025. This study explores the safety and effectiveness of RPT904, a novel immunology-based treatment, and represents a key milestone in RAPT’s efforts to develop therapies for inflammatory and immunological diseases. A live webcast and slide presentation will begin at 8:30 a.m. ET on October 20. Investors and analysts can pre-register online to receive phone numbers and passcodes for the conference call, which will include a live Q&A session. The webcast and an audio archive will be accessible at RAPT’s investor website: https://investors.rapt.com/events-and-presentations. This update follows RAPT’s focus on translating immunology research into new medicines for patients.Read AnnouncementFDA Clearance - September 29,2025Fda Clearance NDADrug: RPT904Announced Date: September 29, 2025Indication: Food AllergyAnnouncementRAPT Therapeutics, Inc announced that the U.S. Food and Drug Administration (FDA) has cleared RAPT's Investigational New Drug (IND) Application to proceed to a Phase 2b clinical trial of RPT904 for the treatment of patients with food allergy.AI SummaryRAPT Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application to begin a Phase 2b clinical trial of RPT904 for treating food allergies. RPT904 is a novel, half-life–extended anti-IgE monoclonal antibody designed to inhibit free and cell-bound human immunoglobulin E, a key driver of allergic reactions. The Phase 2b “prestIgE” trial will be a randomized, double-blind, placebo-controlled study comparing two dosing schedules of RPT904—every eight weeks (Q8W) or every 12 weeks (Q12W), each with a loading dose at Week 2—against placebo in a 2:2:1 ratio. Part 1 will enroll about 100 participants with IgE-mediated allergies to peanut, milk, egg, walnut or cashew and run for 24 weeks, measuring response by oral food challenge. In Part 2, responders continue treatment through Week 48, after which all participants undergo another challenge and a 16-week safety follow-up. RAPT aims to start this trial by year-end, moving closer to a best-in-class option for the large, underserved food allergy community.Read Announcement Rapt Therapeutics FDA Events - Frequently Asked Questions Has Rapt Therapeutics received FDA approval? As of now, Rapt Therapeutics (RAPT) has not received any FDA approvals for its therapy in the last two years. What drugs has Rapt Therapeutics submitted to the FDA? In the past two years, Rapt Therapeutics (RAPT) has reported FDA regulatory activity for RPT904. What is the most recent FDA event for Rapt Therapeutics? The most recent FDA-related event for Rapt Therapeutics occurred on October 27, 2025, involving RPT904. The update was categorized as "Trial Initiation," with the company reporting: " RAPT Therapeutics, Inc announced that it has initiated the randomized, double-blind, placebo-controlled prestIgE Phase 2b clinical trial of ozureprubart (formerly RPT904) in IgE-mediated food allergy." What conditions do Rapt Therapeutics' current drugs treat? Currently, Rapt Therapeutics has one therapy (RPT904) targeting the following condition: Food Allergy. More FDA Event Resources from MarketBeat FDA Calendars Recent FDA Drug Approval Calendar Upcoming FDA Events & PDUFA Dates Calendar Companies With Recent FDA Events Scholar Rock FDA EventsAC Immune FDA EventsAlector FDA EventsAlzamend Neuro FDA EventsArcutis Biotherapeutics FDA EventsBioNTech FDA EventsHarrow FDA EventsIonis Pharmaceuticals FDA EventsMilestone Pharmaceuticals FDA EventsRadiopharm Theranostics FDA EventsRein Therapeutics FDA EventsTurn Therapeutics FDA EventsNuvation Bio FDA EventsHumacyte FDA EventsModerna FDA Events FDA Event Stage Terminology & Abbreviation Guide NDA: New Drug Application ANDA: Abbreviated New Drug Application sNDA: Supplemental New Drug Application BLA: Biologics License Application sBLA: Supplemental Biologics License Application FDA Approved: Approved by the FDA EMA: European Medicines Agency CE Mark: European Union Certification NMPA: China National Medical Products Administration MHLW: Japanese Ministry of Health FDA Meeting: Consultation with FDA Pre-IND: Pre-Investigational New Drug Meeting Breakthrough Therapy: Special FDA designation for promising therapies Fast Track: Accelerated FDA approval pathway Orphan Drug: Designation for rare disease treatments RPD: Rare Pediatric Disease Designation RMAT: Regenerative Medicine Advanced Therapy DSMB Review: Data Safety Monitoring Board Review IDMC Review: Independent Data Monitoring Committee MAA: MHRA Marketing Authorization Application RTF: Refusal to File (Rejected Application) 510(k): FDA Clearance for Medical Devices Rolling Submission: Staggered regulatory review process Related Companies Erasca FDA Events Scholar Rock FDA Events Xenon Pharmaceuticals FDA Events Kiniksa Pharmaceuticals International FDA Events PTC Therapeutics FDA Events Ligand Pharmaceuticals FDA Events Travere Therapeutics FDA Events Grifols FDA Events CRISPR Therapeutics FDA Events ACADIA Pharmaceuticals FDA Events Stock Lists Biotechnology StocksCompare Biotech StocksCompare Healthcare StocksCompare Pharmaceutical StocksHealthcare Stocks FDA progress for NASDAQ:RAPT last updated on 10/27/2025 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data. From Our Partners23,281 stocks. Only ONE survived.One American energy producer just cleared a screen of 23281 stocks for elite operating profits, double-digit r...Monument Traders Alliance | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredYour withdrawal order could cost you in taxesIf you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answe...SmartAsset | SponsoredTrump’s New Currency ResetTrump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 i...Porter & Company | SponsoredElon Musk, Peter Thiel, Sam Altman Are Teaming Up to Back THIS New AIElon Musk, Peter Thiel, and Sam Altman are backing a new AI use case discovered at MIT that has already identi...Stansberry Research | SponsoredA $382 trillion migration and the position no one is talking aboutTrump just signed a law requiring America's entire $382 trillion financial system to migrate to a new money ne...Awesomely | Sponsored"Second Wave” Hitting Iran Soon? Wall Street Issues WarningAnalysts at Goldman Sachs and Morgan Stanley are warning that a quiet domestic threat - unrelated to overseas ...TradeSmith | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rapt Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share Rapt Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trial Initiation - October 27,2025Trial Initiation Phase 2bDrug: RPT904Announced Date: October 27, 2025Indication: Food AllergyAnnouncement RAPT Therapeutics, Inc announced that it has initiated the randomized, double-blind, placebo-controlled prestIgE Phase 2b clinical trial of ozureprubart (formerly RPT904) in IgE-mediated food allergy.AI SummaryRAPT Therapeutics, Inc. has launched the prestIgE Phase 2b trial of ozureprubart (formerly RPT904), a half-life extended anti-IgE antibody, in patients with IgE-mediated food allergies. This randomized, double-blind, placebo-controlled study will enroll about 100 participants across 30 sites in the U.S., Canada and Australia. Participants with peanut, milk, egg, walnut or cashew allergies will receive ozureprubart subcutaneously every eight or 12 weeks (with a second loading dose) or placebo, in a 2:2:1 ratio. The primary endpoint is the percentage of subjects who reach a prespecified tolerance threshold during a double-blind, placebo-controlled oral food challenge at Week 24. Brian Wong, M.D., Ph.D., RAPT’s CEO, said the trial builds on strong early data and aims to offer patients a more durable, less frequent dosing option. Hugh Sampson, M.D., highlighted ozureprubart’s potential as a transformative bio-better to omalizumab.Read Announcement
Top-line results - October 20,2025Top-Line Results Phase 2Drug: RPT904Announced Date: October 20, 2025Indication: Food AllergyAnnouncementRAPT Therapeutics, Inc. announced positive topline data from Jeyou's Phase 2 trial of RPT904 (JYB1904) as monotherapy in chronic spontaneous urticaria (CSU).AI SummaryRAPT Therapeutics announced positive topline data from Shanghai Jeyou’s Phase 2 trial of RPT904 (JYB1904) in adults with chronic spontaneous urticaria (CSU). In this randomized, double-blind study, 137 patients received 300 mg of RPT904 either every eight weeks (Q8W) or as a single dose every twelve weeks (Q12W), while a comparator arm received 300 mg of omalizumab every four weeks (Q4W). Both RPT904 schedules produced numerically greater reductions in the seven-day UAS7 symptom score at Weeks 8, 12 and 16, and higher rates of complete symptom relief (UAS7 = 0), compared to omalizumab Q4W. Efficacy was sustained through Week 16 after one RPT904 dose. RPT904 was well tolerated, with no serious adverse events related to the study drug. Based on these results, Jeyou plans to advance RPT904 into Phase 3 development in China, and RAPT will discuss its global Phase 3 path with the FDA. RAPT will host a conference call at 8:30 am ET today to review these data.Read Announcement
Top-line data - October 19,2025Top-Line Data Phase 2Drug: RPT904Announced Date: October 19, 2025Indication: Food AllergyAnnouncementRAPT Therapeutics, Inc. announced that the Company plans to report topline data from the Phase 2 clinical trial of RPT904 (JYB1904) in patients with Chronic Spontaneous Urticaria (CSU) conducted by its partner, Shanghai Jeyou Pharmaceutical Co., Ltd.AI SummaryRAPT Therapeutics, Inc. plans to share topline results from its partner Shanghai Jeyou Pharmaceutical’s Phase 2 clinical trial of RPT904 (JYB1904) in patients with Chronic Spontaneous Urticaria (CSU). The company will release data in a premarket press release and webcast on Monday, October 20, 2025. This study explores the safety and effectiveness of RPT904, a novel immunology-based treatment, and represents a key milestone in RAPT’s efforts to develop therapies for inflammatory and immunological diseases. A live webcast and slide presentation will begin at 8:30 a.m. ET on October 20. Investors and analysts can pre-register online to receive phone numbers and passcodes for the conference call, which will include a live Q&A session. The webcast and an audio archive will be accessible at RAPT’s investor website: https://investors.rapt.com/events-and-presentations. This update follows RAPT’s focus on translating immunology research into new medicines for patients.Read Announcement
FDA Clearance - September 29,2025Fda Clearance NDADrug: RPT904Announced Date: September 29, 2025Indication: Food AllergyAnnouncementRAPT Therapeutics, Inc announced that the U.S. Food and Drug Administration (FDA) has cleared RAPT's Investigational New Drug (IND) Application to proceed to a Phase 2b clinical trial of RPT904 for the treatment of patients with food allergy.AI SummaryRAPT Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application to begin a Phase 2b clinical trial of RPT904 for treating food allergies. RPT904 is a novel, half-life–extended anti-IgE monoclonal antibody designed to inhibit free and cell-bound human immunoglobulin E, a key driver of allergic reactions. The Phase 2b “prestIgE” trial will be a randomized, double-blind, placebo-controlled study comparing two dosing schedules of RPT904—every eight weeks (Q8W) or every 12 weeks (Q12W), each with a loading dose at Week 2—against placebo in a 2:2:1 ratio. Part 1 will enroll about 100 participants with IgE-mediated allergies to peanut, milk, egg, walnut or cashew and run for 24 weeks, measuring response by oral food challenge. In Part 2, responders continue treatment through Week 48, after which all participants undergo another challenge and a 16-week safety follow-up. RAPT aims to start this trial by year-end, moving closer to a best-in-class option for the large, underserved food allergy community.Read Announcement
